PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed
This article was originally published in The Pink Sheet Daily
A change in projected discounts resulted from ICER’s decision to broaden its consideration of the benefit of PCSK9 treatment to span a patient’s lifetime, including outcomes in patients over 75.
You may also be interested in...
The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.
Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.
Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.